JP7445910B2 - Oral compositions, oral care products, and foods containing oral resident bacteria regulators - Google Patents
Oral compositions, oral care products, and foods containing oral resident bacteria regulators Download PDFInfo
- Publication number
- JP7445910B2 JP7445910B2 JP2017128123A JP2017128123A JP7445910B2 JP 7445910 B2 JP7445910 B2 JP 7445910B2 JP 2017128123 A JP2017128123 A JP 2017128123A JP 2017128123 A JP2017128123 A JP 2017128123A JP 7445910 B2 JP7445910 B2 JP 7445910B2
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- oral
- pathogenic bacteria
- strain
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000894006 Bacteria Species 0.000 title claims description 135
- 239000000203 mixture Substances 0.000 title claims description 52
- 235000013305 food Nutrition 0.000 title claims description 17
- 210000000214 mouth Anatomy 0.000 claims description 62
- 244000052616 bacterial pathogen Species 0.000 claims description 59
- 230000000844 anti-bacterial effect Effects 0.000 claims description 54
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 241001134658 Streptococcus mitis Species 0.000 claims description 26
- 241000194025 Streptococcus oralis Species 0.000 claims description 22
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000645 desinfectant Substances 0.000 claims description 9
- 230000003239 periodontal effect Effects 0.000 claims description 9
- 239000003899 bactericide agent Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 8
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 6
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical group [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 6
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 claims description 4
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 claims description 4
- 241001135221 Prevotella intermedia Species 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 3
- 229960001950 benzethonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 238000012360 testing method Methods 0.000 description 36
- 239000002324 mouth wash Substances 0.000 description 35
- 229940051866 mouthwash Drugs 0.000 description 24
- -1 s Species 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 208000028169 periodontal disease Diseases 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 239000013065 commercial product Substances 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000000606 toothpaste Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000001013 cariogenic effect Effects 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000025157 Oral disease Diseases 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 208000030194 mouth disease Diseases 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 208000002925 dental caries Diseases 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000000551 dentifrice Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 235000015218 chewing gum Nutrition 0.000 description 4
- 229940112822 chewing gum Drugs 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- 241000605909 Fusobacterium Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000007027 Oral Candidiasis Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- CFAKWWQIUFSQFU-UHFFFAOYSA-N 2-hydroxy-3-methylcyclopent-2-en-1-one Chemical compound CC1=C(O)C(=O)CC1 CFAKWWQIUFSQFU-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000011203 Origanum Nutrition 0.000 description 2
- 241000193987 Streptococcus sobrinus Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000222126 [Candida] glabrata Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 208000032343 candida glabrata infection Diseases 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 239000010634 clove oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008369 fruit flavor Substances 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- IAEGWXHKWJGQAZ-UHFFFAOYSA-N trimethylpyrazine Chemical compound CC1=CN=C(C)C(C)=N1 IAEGWXHKWJGQAZ-UHFFFAOYSA-N 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- JHEPBQHNVNUAFL-AATRIKPKSA-N (e)-hex-1-en-1-ol Chemical compound CCCC\C=C\O JHEPBQHNVNUAFL-AATRIKPKSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- MVOSYKNQRRHGKX-UHFFFAOYSA-N 11-Undecanolactone Chemical compound O=C1CCCCCCCCCCO1 MVOSYKNQRRHGKX-UHFFFAOYSA-N 0.000 description 1
- 239000001837 2-hydroxy-3-methylcyclopent-2-en-1-one Substances 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- TWXUTZNBHUWMKJ-UHFFFAOYSA-N Allyl cyclohexylpropionate Chemical compound C=CCOC(=O)CCC1CCCCC1 TWXUTZNBHUWMKJ-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 244000182807 Mentha suaveolens Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241001529744 Origanum Species 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- LQKRYVGRPXFFAV-UHFFFAOYSA-N Phenylmethylglycidic ester Chemical compound CCOC(=O)C1OC1(C)C1=CC=CC=C1 LQKRYVGRPXFFAV-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- APTGPWJUOYMUCE-UHFFFAOYSA-N S-Ethyl thioacetate Chemical compound CCSC(C)=O APTGPWJUOYMUCE-UHFFFAOYSA-N 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- 239000010636 coriander oil Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、口腔常在菌調整剤を含む口腔用組成物に関し、詳しくは、口腔内における有用常在菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整可能な、優れた選択的抗菌効果を奏する、口腔常在菌調整剤を含む口腔用組成物、口腔ケア製品及び食品に関する。 The present invention relates to an oral cavity composition containing an oral resident bacteria regulating agent, and more specifically, to a composition that maintains useful resident bacteria in the oral cavity and selectively exerts an antibacterial effect against pathogenic bacteria in the oral cavity. The present invention relates to an oral composition, an oral care product, and a food product containing an oral resident bacteria regulating agent that exhibits an excellent selective antibacterial effect and can be adjusted to maintain a good balance of resident bacteria in the oral cavity.
ヒトの口腔内には様々な細菌が共生しており、常在細菌叢と呼ばれる細菌集団を形成している。常在細菌叢には病原菌や日和見感染菌が存在しているが、細菌叢のバランスが保たれている状態では、これらの細菌を原因とする疾患は抑制されており、いわゆる健康な状態にある。しかし、食生活の変化や抗生剤の摂取、ストレス、加齢などを原因として細菌叢のバランスが崩れることにより、病原性細菌や日和見感染菌が増加し疾患を発症する。そのため、疾患の抑制には病原性細菌を選択的に抑制し、非病原性の常在菌（特に有用常在菌）を優勢にすることで常在細菌叢のバランスを保つことが重要である。 Various bacteria coexist in the human oral cavity, forming a bacterial population called the resident bacterial flora. Pathogenic bacteria and opportunistic bacteria exist in the resident flora, but when the flora is in balance, diseases caused by these bacteria are suppressed, and the body is in a so-called healthy state. . However, when the balance of the bacterial flora is disrupted due to changes in diet, intake of antibiotics, stress, aging, etc., pathogenic bacteria and opportunistic bacteria increase, leading to the development of diseases. Therefore, in order to control the disease, it is important to maintain the balance of the resident flora by selectively suppressing pathogenic bacteria and making non-pathogenic resident bacteria (especially beneficial resident bacteria) predominant. .
ヒトの口腔内では７００種を超える極めて多種類の口腔内細菌が見出されている。ヒトの口腔内に存在する細菌の中で、病原性を示す細菌は、歯周病原性細菌であるポルフィロモナス ジンジバリス（Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓ）、う蝕の原因菌であるストレプトコッカス ミュータンス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｕｔａｎｓ）を代表とする数種類の細菌に過ぎない。口腔内細菌の残りのほとんどは、通常、ヒトへの病原性を示さないストレプトコッカス ミティス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｉｔｉｓ、以下、Ｓ．ｍｉｔｉｓとも呼ぶ。）、ストレプトコッカス オラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｏｒａｌｉｓ、以下、Ｓ．ｏｒａｌｉｓとも呼ぶ。）を代表とするミティス（Ｍｉｔｉｓ）グループなどのストレプトコッカス（連鎖球菌）属細菌などの通常、口腔内においては非病原性の常在菌である。従って、口腔疾患の予防には、口腔内において、非病原性の口腔内常在菌の生育に影響を与えることなく選択的に口腔内病原性細菌の生育を抑制することが重要となる。 More than 700 types of oral bacteria have been found in the human oral cavity. Among the bacteria that exist in the human oral cavity, pathogenic bacteria include Porphyromonas gingivalis, a periodontal pathogen, and Streptococcus mutans, a caries-causing bacterium. These are just a few representative types of bacteria. Most of the remaining oral bacteria are Streptococcus mitis (hereinafter also referred to as S. mitis) and Streptococcus oralis (hereinafter also referred to as S. oralis), which are not normally pathogenic to humans. Bacteria belonging to the genus Streptococcus, such as the Mitis group typified by Mitis, are normally non-pathogenic and resident bacteria in the oral cavity. Therefore, in order to prevent oral diseases, it is important to selectively suppress the growth of oral pathogenic bacteria in the oral cavity without affecting the growth of non-pathogenic oral bacteria.
特に、上述したストレプトコッカス ミティスやストレプトコッカス オラリスなどの非病原性常在菌のミティスグループの連鎖球菌は、上記したう蝕や歯周病の原因菌の歯面付着に関与したり、抗菌作用を有することが知られており（非特許文献１参照）、口腔疾患抑制に作用する有用な常在菌である。 In particular, streptococci belonging to the non-pathogenic resident bacteria group Streptococcus mitis, such as Streptococcus mitis and Streptococcus oralis mentioned above, are involved in the attachment of the above-mentioned caries and periodontal disease-causing bacteria to tooth surfaces, and have antibacterial effects. (Refer to Non-Patent Document 1), and is a useful resident bacteria that acts to suppress oral diseases.
続いて、上述したストレプトコッカス ミティス及びストレプトコッカス オラリスについて具体的に説明する。非特許文献１に記載されているように、バイオフィルムは以下のように形成される。歯の表面を構成するエナメル質の表面には、まずペリクル（歯の表面上の唾液タンパク質の層）が形成される。ペリクルのもとになるのは唾液中のカルシウム結合タンパク質（ｃａｌｃｉｕｍ－ｂｉｎｄｉｎｇ ｐｒｏｔｅｉｎｓ；ＣＢＰ）であり、この物質はエナメル質のカルシウムに親和性をもっている。これが歯のエナメル質上に並ぶと、それに親和性をもつ細菌、すなわちストレプトコッカス ミティス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｉｔｉｓ）、ストレプトコッカス オラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｏｒａｌｉｓ）などの菌が選択的に付着してくる。これらの菌は、ｅａｒｌｙ ｃｏｌｏｎｉｚｅｒ（早期定着菌群）と呼ばれる。これが常在菌、すなわちわれわれが守り育てなければならない細菌群で、例えば大腸におけるビフィズス菌に相当する。とくにＳ．ｍｉｔｉｓは、口腔内細菌を培養した場合に、口腔内細菌全量の９割を占める。 Next, the above-mentioned Streptococcus mitis and Streptococcus oralis will be specifically explained. As described in Non-Patent Document 1, biofilms are formed as follows. A pellicle (a layer of salivary protein on the tooth surface) is first formed on the surface of the enamel that makes up the tooth surface. The source of the pellicle is calcium-binding proteins (CBP) in saliva, and this substance has an affinity for calcium in enamel. When these are lined up on tooth enamel, bacteria that have an affinity for them, such as Streptococcus mitis and Streptococcus oralis, selectively adhere to them. These bacteria are called early colonizers. These are the resident bacteria, a group of bacteria that we must protect and nurture, and correspond to, for example, the bifidobacteria in the large intestine. Especially S. When oral bacteria are cultured, S. mitis accounts for 90% of the total amount of oral bacteria.
また、非特許文献１では、無菌状態は実は非常に危険な状態であるとの理解が必要であり、あくまで常在菌が口腔内に存在することが大切であり、常在菌叢の維持という観点からは、強力な抗菌剤を口腔内全体に使うのはよくないことであると述べられている。 In addition, Non-Patent Document 1 states that it is necessary to understand that a sterile state is actually a very dangerous state, and that it is important that resident bacteria exist in the oral cavity, and that it is important to maintain the resident bacterial flora. From this point of view, it is stated that it is not a good idea to use strong antibacterial agents throughout the oral cavity.
歯周病等の予防用途として例えば、一般的な呼称としてマウスウォッシュと呼ばれる抗菌作用を有する洗口液が市販されているが、このような洗口液のなかには、種々の抗菌剤が含まれている。洗口液に含まれる幾つかの抗菌剤においては口腔内の細菌全般に対して広く作用し、有用常在菌をも殺菌してしまい、口腔内における常在菌のバランスが崩れてしまうものもある。そのため、口腔内における有用常在菌を死滅させること無く残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整可能な、優れた選択的抗菌効果を奏する口腔用組成物、口腔ケア製品及び食品が求められている。 For example, mouthwashes with antibacterial effects, commonly called mouthwashes, are commercially available for use in preventing periodontal disease, etc., but these mouthwashes contain various antibacterial agents. There is. Some antibacterial agents contained in mouthwashes have a wide range of effects against all bacteria in the oral cavity, sterilizing even beneficial resident bacteria, and some may disrupt the balance of resident bacteria in the oral cavity. be. Therefore, we maintain a good balance of the indigenous bacteria in the oral cavity by allowing the beneficial bacteria in the oral cavity to remain without being killed, and by selectively exerting an antibacterial effect against pathogenic bacteria in the oral cavity. There is a need for oral compositions, oral care products, and foods that exhibit superior selective antibacterial effects that can be tailored to specific needs.
そこで、本発明は、上記現状の課題に鑑みてなされたものであり、口腔内における有用常在菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整可能な、優れた選択的抗菌効果を奏する口腔常在菌調整剤を含む口腔用組成物、口腔ケア製品及び食品を提供することを目的とする。 Therefore, the present invention has been made in view of the above-mentioned current problems, and is designed to maintain useful indigenous bacteria in the oral cavity and selectively exert an antibacterial effect against pathogenic bacteria in the oral cavity. The purpose of the present invention is to provide oral compositions, oral care products, and foods that contain an oral resident bacteria regulating agent that exhibits excellent selective antibacterial effects that can be adjusted to maintain a good balance of resident bacteria in the oral cavity. shall be.
本発明の解決しようとする課題は以上の如くであり、次にこの課題を解決するための手段を説明する。 The problem to be solved by the present invention is as described above, and next, means for solving this problem will be explained.
本発明者らは、前記課題を解決するため種々の検討を重ねた結果、ヒトの唾液中に存在する特定の乳酸菌株について、所定の処方において口腔内における有用常在菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するものがあることを見出し、本発明を完成するに至った。 As a result of various studies in order to solve the above problems, the present inventors have determined that a specific lactic acid bacteria strain present in human saliva can be used in a predetermined formulation to retain useful indigenous bacteria in the oral cavity and to select The present inventors have discovered that there are some substances that have an antibacterial effect against pathogenic bacteria in the oral cavity, and have completed the present invention.
即ち、本発明の口腔常在菌調整剤を含む口腔用組成物においては、
ラクトバチルス・ラムノーサスＫＯ３株（ＮＩＴＥＢＰ－７７１）の菌体、菌体培養物、又はこれらの抽出物を口腔常在菌調整剤として含有し、
前記ラクトバチルス・ラムノーサスＫＯ３株の組成物全体に対する配合率が０．６～２．５重量％であり、
口腔内の非病原性細菌の生育を抑制することなく病原性細菌の生育を抑制するように選択的に作用する上記口腔常在菌調整剤を含む口腔用組成物であって、
前記病原性細菌が、歯周病原性細菌であるポルフィロモナス ジンジバリス及び／又はプレボテラ インターメディアであり、
前記非病原性細菌が、ストレプトコッカス ミティス及びストレプトコッカス オラリスから選ばれるミティスグループの連鎖球菌であり、
前記歯周病原性細菌と共に前記非病原性細菌を殺菌する非選択的な殺菌作用を奏する非選択的殺菌剤を含まない、口腔内の非病原性細菌の生育を抑制することなく病原性細菌の生育を抑制するように選択的に作用するものである。
That is, in the oral composition containing the oral resident bacteria regulator of the present invention,
Contains Lactobacillus rhamnosus KO3 strain (NITEBP-771) bacterial cells, bacterial cell culture, or extracts thereof as an oral resident bacteria regulator,
The blending ratio of the Lactobacillus rhamnosus KO3 strain to the entire composition is 0.6 to 2.5% by weight,
An oral composition comprising the oral cavity resident bacteria regulator that selectively acts to suppress the growth of pathogenic bacteria without suppressing the growth of non-pathogenic bacteria in the oral cavity,
The pathogenic bacteria are periodontal pathogenic bacteria Porphyromonas gingivalis and/or Prevotella intermedia,
the non-pathogenic bacterium is a streptococcus of the mitis group selected from Streptococcus mitis and Streptococcus oralis;
It does not contain a non-selective bactericidal agent that has a non-selective bactericidal effect that sterilizes the non-pathogenic bacteria together with the periodontal pathogenic bacteria. It acts selectively to suppress growth .
本発明の口腔常在菌調整剤を含む口腔用組成物においては、
前記非選択的殺菌剤は、塩化セチルピリジニウム、塩化ベンゼトニウム、塩化ベンザルコニウム、又はイソプロピルメチルフェノールから選択されるものである。
In the oral composition containing the oral resident bacteria regulator of the present invention,
The non-selective disinfectant is selected from cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, or isopropylmethylphenol .
本発明の口腔内の非病原性細菌の生育を抑制することなく病原性細菌の生育を抑制するように選択的に作用する口腔ケア製品においては、上記口腔用組成物を含むものである。 The oral care product of the present invention that selectively acts to suppress the growth of pathogenic bacteria without suppressing the growth of non-pathogenic bacteria in the oral cavity contains the above-mentioned oral composition.
本発明の口腔内の非病原性細菌の生育を抑制することなく病原性細菌の生育を抑制するように選択的に作用する食品においては、上記口腔用組成物を含むものである。 The food of the present invention that selectively acts to inhibit the growth of pathogenic bacteria without inhibiting the growth of non-pathogenic bacteria in the oral cavity contains the oral composition described above.
本発明によれば、口腔内における非病原性細菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整可能な、優れた選択的抗菌効果を奏する口腔常在菌調整剤を含む口腔用組成物を提供することができる。 According to the present invention, non-pathogenic bacteria in the oral cavity remain, and an antibacterial effect is selectively exerted on pathogenic bacteria in the oral cavity to maintain a good balance of resident bacteria in the oral cavity. It is possible to provide an oral cavity composition containing an oral resident bacteria regulating agent that exhibits excellent selective antibacterial effects that can be adjusted to
次に、発明の実施の形態を説明する。 Next, embodiments of the invention will be described.
本発明の口腔用組成物は、口腔常在菌調整作用を奏する口腔常在菌調整剤の一例であるラクトバチルス・ラムノーサスに属する乳酸菌の菌株を含むものである。詳細は後述するが、本発明の口腔用組成物は、口腔内における非病原性細菌である有用常在菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整するように作用する。すなわち、本発明の口腔用組成物は、選択的抗菌作用を有しており、口腔内の非病原性細菌の生育に影響を与えることなく選択的に歯周病原性細菌の生育を抑制する優れた抗菌効果を奏する。 The oral composition of the present invention contains a strain of lactic acid bacteria belonging to Lactobacillus rhamnosus, which is an example of an oral resident bacteria regulating agent that exhibits an oral resident bacteria regulating effect. Although the details will be described later, the oral composition of the present invention not only retains useful non-pathogenic bacteria in the oral cavity, but also selectively exerts an antibacterial effect against pathogenic bacteria in the oral cavity. It acts to maintain a good balance of resident bacteria in the oral cavity. That is, the oral composition of the present invention has a selective antibacterial effect, and has the advantage of selectively suppressing the growth of periodontal pathogenic bacteria without affecting the growth of non-pathogenic bacteria in the oral cavity. It also has an antibacterial effect.
ここで、「口腔常在菌調整」とは、上述のように口腔内における有用常在菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整することであり、具体的には、病原性細菌に対して選択的抗菌作用を奏することで非病原性常在菌の生育に影響が及ばないことによって、口腔内の常在菌叢の菌叢バランスを病原性の低い菌叢に調整することである。
また、「選択的抗菌」とは、口腔内の病原性細菌に対して抗菌活性を有し、その一方で非病原性細菌に対する抗菌活性は有さないことによって、非病原性細菌の生育を抑制することなく病原性細菌の生育を選択的に抑制する抗菌作用である。
Here, "regulating oral resident bacteria" refers to maintaining useful resident bacteria in the oral cavity as described above, as well as selectively exerting an antibacterial effect against pathogenic bacteria in the oral cavity. The aim is to maintain a good balance of resident bacteria in the bacteria, and specifically, by exerting a selective antibacterial effect against pathogenic bacteria, the growth of non-pathogenic resident bacteria is not affected. By doing so, the balance of the normal bacterial flora in the oral cavity is adjusted to a bacterial flora with low pathogenicity.
In addition, "selective antibacterial" means that it has antibacterial activity against pathogenic bacteria in the oral cavity, but does not have antibacterial activity against non-pathogenic bacteria, thereby suppressing the growth of non-pathogenic bacteria. It has an antibacterial effect that selectively suppresses the growth of pathogenic bacteria without causing any damage.
本発明における口腔常在菌調整剤は、抗菌作用を有するため口腔用組成物の抗菌成分として使用可能である。
なお、本実施形態において、「抗菌」とは、細菌及び真菌類の殺菌又除菌、もしくはこれらの発生・生育・増殖を抑制することを含めて、最も広義に解釈されるべきであり、如何なる意味においても限定されない。
The oral cavity resident bacteria regulating agent of the present invention has an antibacterial effect and can therefore be used as an antibacterial component of an oral composition.
In addition, in this embodiment, "antibacterial" should be interpreted in the broadest sense, including the sterilization or eradication of bacteria and fungi, or the suppression of their occurrence, growth, and proliferation. It is not limited in meaning either.
本発明に関するラクトバチルス・ラムノーサスに属する乳酸菌の菌株は乳酸菌の一例である。この菌株は、独立行政法人製品評価技術基盤機構 特許微生物寄託センターに寄託されている。
具体的には、ラクトバチルス・ラムノーサスの一例として、当該特許微生物寄託センターにＮＩＴＥ ＢＰ－７７１として寄託されたラクトバチルス・ラムノーサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）ＫＯ３株が挙げられる（以下、単にＫＯ３株ともいう）。
The strain of lactic acid bacteria belonging to Lactobacillus rhamnosus related to the present invention is an example of lactic acid bacteria. This strain has been deposited at the Patent Microorganism Depositary of the National Institute of Technology and Evaluation.
Specifically, an example of Lactobacillus rhamnosus is the Lactobacillus rhamnosus KO3 strain deposited at the Patent Microorganism Depositary as NITE BP-771 (hereinafter also simply referred to as KO3 strain).
ＫＯ３株は、ヒト唾液中から分離されたものであり、ヒト由来の乳酸菌である。ＫＯ３株は、１６Ｓ ｒＲＮＡの塩基配列がラクトバチルス・ラムノーサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）ｓｔｒａｉｎ ＩＤＣＣ３２０１の塩基配列と１４８５／１４８５の間で１００％の相同性を示し、グラム染色後の顕鏡下においてグラム陽性桿菌の様相を呈することから、ラクトバチルス・ラムノーサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）と同定された。ＫＯ３株の主な菌学的性質を以下に示す。
１）グラム陽性乳酸桿菌、２）ホモ型乳酸発酵、３）カタラーゼ陰性、４）芽胞形成能無し、５）好気条件下でも培養可、６）菌体外多糖類を産生。
The KO3 strain was isolated from human saliva and is a human-derived lactic acid bacterium. The KO3 strain shows 100% homology between the base sequence of Lactobacillus rhamnosus (Lactobacillus rhamnosus) strain IDCC3201 and 1485/1485, and the KO3 strain shows 100% homology between 1485/1485 and the base sequence of Lactobacillus rhamnosus strain IDCC3201. Based on its appearance, it was identified as Lactobacillus rhamnosus. The main mycological properties of the KO3 strain are shown below.
1) Gram-positive lactobacillus, 2) Homotype lactic acid fermentation, 3) Catalase negative, 4) No spore-forming ability, 5) Can be cultured under aerobic conditions, 6) Produces extracellular polysaccharides.
本発明においては、上記乳酸菌の菌体を、乳酸菌培養の常法に従って培養し、得られた培養物から遠心分離等の集菌手段によって分離されたものをそのまま用いることのみならず、当該培養・発酵液（培養上清）、その濃縮液や、菌体を酵素や物理的手段を用いて処理した細胞質や細胞壁画分も用いることができる。また、生菌体のみならず死菌体であってもよい。 In the present invention, the cells of the lactic acid bacteria described above are cultured according to a conventional method for culturing lactic acid bacteria, and the resulting culture is separated by a bacterial collection means such as centrifugation, and not only can it be used as it is, but also the cultured and Fermentation broth (culture supernatant), its concentrate, and cytoplasm and cell wall fraction obtained by treating bacterial cells with enzymes or physical means can also be used. Furthermore, not only viable cells but also dead cells may be used.
本発明のＫＯ３株を培養する培地には、果汁培地、野菜汁培地、牛乳培地、脱脂粉乳培地又は乳成分を含む培地、これを含まない半合成培地等種々の培地を用いることができる。このような培地としては、脱脂乳を還元して加熱殺菌した還元脱脂乳培地、酵母エキスを添加した脱脂粉乳培地、ＭＲＳ培地、ＧＡＭ培地等を例示することができる。
培養方法は、静置培養又はｐＨを一定にした中和培養や、回分培養及び連続培養等、菌体が良好に生育する条件であれば、特に制限はない。
As a medium for culturing the KO3 strain of the present invention, various media can be used, such as a fruit juice medium, a vegetable juice medium, a milk medium, a skim milk powder medium, a medium containing a milk component, and a semi-synthetic medium not containing this. Examples of such a medium include a reduced skim milk medium obtained by reducing and heat sterilizing skim milk, a skim milk powder medium supplemented with yeast extract, an MRS medium, a GAM medium, and the like.
The culture method is not particularly limited as long as the conditions allow for good growth of the bacterial cells, such as static culture, neutralized culture with a constant pH, batch culture, and continuous culture.
本発明のＫＯ３株の菌体又は菌体培養物の抽出物とは、菌体又は菌体培養物を、溶媒抽出することにより得られる各種溶剤抽出液、その希釈液、その濃縮液又はその乾燥末を意味するものである。 The extract of bacterial cells or bacterial cell cultures of the KO3 strain of the present invention refers to various solvent extracts obtained by solvent extraction of bacterial cells or bacterial cell cultures, diluted solutions thereof, concentrated solutions thereof, or dried extracts thereof. It means the end.
本発明の抽出物を得るために用いられる抽出溶剤としては、極性溶剤、非極性溶剤のいずれをも使用することができ、これらを混合して用いることもできる。例えば、水；メタノール、エタノール、プロパノール、ブタノール等のアルコール類；プロピレングリコール、ブチレングリコール等の多価アルコール類；アセトン、メチルエチルケトン等のケトン類；酢酸メチル、酢酸エチル等のエステル類；テトラヒドロフラン、ジエチルエーテル等の鎖状及び環状エーテル類；ポリエチレングリコール等のポリエーテル類；ヘキサン、シクロヘキサン、石油エーテル等の炭化水素類；ベンゼン、トルエン等の芳香族炭化水素類；ピリジン類等が挙げられ、このうち、酢酸エチル等のエステル類、エタノール等のアルコール類が好ましい。 As the extraction solvent used to obtain the extract of the present invention, either a polar solvent or a non-polar solvent can be used, and a mixture of these solvents can also be used. For example, water; alcohols such as methanol, ethanol, propanol, and butanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; tetrahydrofuran and diethyl ether chain and cyclic ethers such as; polyethers such as polyethylene glycol; hydrocarbons such as hexane, cyclohexane, petroleum ether; aromatic hydrocarbons such as benzene and toluene; Esters such as ethyl acetate and alcohols such as ethanol are preferred.
抽出条件は、使用する溶剤によっても異なるが、例えば、培養液１質量部に対して１～１０質量部の溶剤を用い、０～５０℃、好ましくは２５～３７℃の温度で、０．５時間～３時間抽出するのが好ましい。 Extraction conditions vary depending on the solvent used, but for example, using 1 to 10 parts by mass of the solvent per 1 part by mass of the culture solution, at a temperature of 0 to 50 °C, preferably 25 to 37 °C, and 0.5 Preferably, the extraction time is between 3 hours and 3 hours.
上記の抽出物は、そのまま用いることもできるが、当該抽出物を希釈、濃縮若しくは凍結乾燥した後、必要に応じて粉末又はペースト状に調製して用いることもできる。また、液々分配等の技術により、適宜精製して用いることもできる。 The above-mentioned extract can be used as it is, but after diluting, concentrating or lyophilizing the extract, it can also be prepared into a powder or paste form and used, if necessary. Furthermore, it can be used after being appropriately purified by techniques such as liquid-liquid distribution.
本発明における、「病原性細菌」としては、う蝕菌、歯周病菌及びカンジダ菌等が挙げられる。う蝕菌、歯周病菌及びカンジダ菌は、例えば、う蝕症；歯肉炎、歯周炎等の歯周病、舌炎、鵞口瘡、口角炎等の口腔カンジダ症等の口腔内疾患を引き起こす原因となる原因菌である。また、本発明における、「非病原性細菌」としては、上述したように、ストレプトコッカス ミティス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｉｔｉｓ）、ストレプトコッカス オラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｏｒａｌｉｓ）を代表とするミティス（Ｍｉｔｉｓ）グループなどのストレプトコッカス（連鎖球菌）属細菌等が挙げられる。 In the present invention, "pathogenic bacteria" include cariogenic bacteria, periodontal disease bacteria, Candida bacteria, and the like. Cariogenic bacteria, periodontal bacteria, and Candida bacteria are causes of oral diseases such as caries; periodontal diseases such as gingivitis and periodontitis; and oral candidiasis such as glossitis, thrush, and angular cheilitis. This is the causative bacteria. In addition, as described above, the "non-pathogenic bacteria" in the present invention include Streptococcus genus, such as the Mitis group represented by Streptococcus mitis and Streptococcus oralis. Examples include bacteria.
また、う蝕菌としては、ストレプトコッカス・ミュータンス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｕｔａｎｓ）、ストレプトコッカス・ソブリナス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｓｏｂｒｉｎｕｓ）、歯周病菌としてはポルフィロモナス・ジンジバリス（Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓ）、プレボテラ・インターメディア（Ｐｒｅｖｏｔｅｌｌａ ｉｎｔｅｒｍｅｄｉａ）、トレポネーマ・デンティコーラ（Ｔｒｅｐｏｎｅｍａ ｄｅｎｔｉｃｏｌａ）、タンネレラ・フォーサイセンシス（Ｔａｎｎｅｒｅｌｌａ ｆｏｒｓｙｔｈｅｎｓｉｓ）、アクチノバチルス・アクチノミセテムコミタンス（Ａｃｔｉｎｏｂａｃｉｌｌｕｓ ａｃｔｉｎｏｍｙｃｅｔｅｍｃｏｍｉｔａｎｓ）、フソバクテリウム・ヌクレアタム（Ｆｕｓｏｂａｃｔｅｒｉｕｍ ｎｕｃｌｅａｔｕｍ）等が挙げられ、カンジダ菌としては、カンジダ・アルビカンス（Ｃａｎｄｉｄａ ａｌｂｉｃａｎｓ）、カンジダ・グラブラータ（Ｃａｎｄｉｄａ ｇｌａｂｒａｔａ）、カンジダ・トロピカリス（Ｃａｎｄｉｄａ ｔｒｏｐｉｃａｌｉｓ）等が挙げられる。 In addition, cariogenic bacteria include Streptococcus mutans and Streptococcus sobrinus, and periodontal disease bacteria include Porphyromonas gingivalis and Prevotella.・Intermedia (Prevotella intermedia), Treponema・Treponema denticola, Tannerella forsythensis, Actinobacillus actinomycetemcomitans, Fusobacterium Examples of Candida include Fusobacterium nucleatum, and Candida albicans. (Candida albicans), Candida glabrata (Candida glabrata), Candida tropicalis (Candida tropicalis), and the like.
特許文献１に示すように、ＫＯ３株は、う蝕菌であるストレプトコッカス・ミュータンス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｕｔａｎｓ）及びストレプトコッカス・ソブリナス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｓｏｂｒｉｎｕｓ）、歯周病菌であるポルフィロモナス・ジンジバリス（Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓ）及びカンジダ菌であるカンジダ・アルビカンス（Ｃａｎｄｉｄａ ａｌｂｉｃａｎｓ）の何れに対しても増殖抑制効果を有する。また、口腔内の歯肉縁下プラークフォーマーとして知られるＦｕｓｏｂａｃｔｅｒｉｕｍ． ｎｕｃｌｅａｔｕｍ等のＦｕｓｏｂａｃｔｅｒｉｕｍ属細菌の増殖を抑制する作用を有する。
従って、当該ＫＯ３株の菌体若しくは菌体培養物又はこれらの抽出物は、口腔内疾患の予防、改善又は治療剤として、或いはう蝕菌、歯周病菌及びカンジダ菌の増殖抑制剤となり得る。斯かる口腔内疾患の予防、改善又は治療剤、蝕菌、歯周病菌及びカンジダ菌の増殖抑制剤は、それ自体で、当該口腔内の病原微生物により引き起こされる、う蝕症、歯周病、口腔カンジダ症等の口腔内疾患の予防、改善又は治療のための、或いはう蝕菌、歯周病菌及びカンジダ菌の増殖抑制のための食品、医薬品、口腔用組成物等として使用でき、或いは食品、医薬品、口腔用組成物に配合するための素材として使用可能である。また、食品は、虫歯、歯周病、その他の口腔内感染症の予防・改善等をコンセプトとし、必要に応じてその旨を表示した健康食品、サプリメント若しくは特定保健用食品等の機能性食品とすることも可能である。
なお、特許文献１には、ＫＯ３株による口腔内の非病原性細菌への影響についての記載はない。
As shown in Patent Document 1, the KO3 strain is a cariogenic bacterium, Streptococcus mutans and Streptococcus sobrinus, and a periodontal disease bacterium, Porphyromonas gingivalis. givalis) and Candida It also has a growth-inhibiting effect on the fungus Candida albicans. In addition, Fusobacterium, which is known as a subgingival plaque former in the oral cavity. It has the effect of suppressing the growth of Fusobacterium bacteria such as Nucleatum.
Therefore, the bacterial cells or bacterial cell culture of the KO3 strain, or their extracts can be used as a prophylactic, ameliorating, or therapeutic agent for oral diseases, or as an agent for inhibiting the growth of cariogenic bacteria, periodontal disease bacteria, and Candida bacteria. Such a preventive, ameliorating or therapeutic agent for oral diseases, an agent for inhibiting the growth of caries, periodontal disease bacteria and candida bacteria, can itself be used to prevent caries, periodontal disease, etc. caused by the pathogenic microorganisms in the oral cavity. It can be used as a food, medicine, oral composition, etc. for the prevention, improvement, or treatment of oral diseases such as oral candidiasis, or for inhibiting the growth of cariogenic bacteria, periodontal disease bacteria, and Candida bacteria, or as a food. It can be used as a material for blending into , pharmaceuticals, and oral compositions. In addition, foods are functional foods such as health foods, supplements, and foods for specified health uses that are designed to prevent and improve tooth decay, periodontal disease, and other oral infections, and are labeled accordingly as necessary. It is also possible to do so.
Note that Patent Document 1 does not describe the influence of the KO3 strain on non-pathogenic bacteria in the oral cavity.
ＫＯ３株は、口膣内疾患の予防、改善または治療等に優れた効果を発揮する有効成分となる。したがって、口膣内疾患の予防、改善又は治療剤として有用である。本発明にかかわるＫＯ３株は、選択的抗菌作用を有する口腔常在菌調整剤として口腔用組成物に好適に配合することができる。 The KO3 strain is an active ingredient that exhibits excellent effects in preventing, improving, or treating orovaginal diseases. Therefore, it is useful as a preventive, ameliorating or therapeutic agent for orovaginal diseases. The KO3 strain according to the present invention can be suitably incorporated into oral compositions as an oral cavity resident bacteria regulator having selective antibacterial activity.
なお、本発明において、口腔用組成物とは、一般的な歯磨剤、洗口剤、口腔用スプレー、口腔用パスタ、軟膏剤、貼付剤等に加え、口腔内に含んで適用する錠剤、グミ、キャンディー、チューインガム、ゲル状の食品なども含むものである。さらに、これらの口腔用組成物を、ペート状、ゲル状、液状、固体状などの各種形態に適宜調製して用いることができる。 In the present invention, oral compositions include general dentifrices, mouth rinses, oral sprays, oral pasta, ointments, patches, etc., as well as tablets and gummies that are applied in the oral cavity. It also includes candy, chewing gum, gel-like foods, etc. Furthermore, these oral compositions can be suitably prepared and used in various forms such as paste, gel, liquid, and solid.
より具体的には、口腔用組成物として練歯磨、液状歯磨、液体歯磨、潤製歯磨等の歯磨剤、洗口液及びマウスウォッシュ等を含む洗口剤、口腔用スプレーの一例であるマウススプレー、口腔用パスタ、口中清涼剤、うがい薬、デンタルリンス、口腔保湿剤、義歯安定剤、義歯潤滑剤、人口唾液、軟膏剤、貼付剤、歯磨きシート／ナップや、錠菓、トローチ、タブレット等の錠剤、カプセル剤、グミ、キャンディー、顆粒、チューインガム、ゲル状の食品、飲料、保存食等の各種剤型に調製し得る。すなわち、本実施形態における口腔用組成物は、その剤型を口腔ケア製品、食品または食品形態等にすることができる。特に、歯磨剤、洗口剤、錠剤、グミ、キャンディー、ゲル状の食品として、特に歯磨剤、洗口剤として好適に調製される。なお、抗菌効果付与の点で錠剤、グミ、キャンディーなどは、口腔内に留まる時間が比較的長いため、好適に使用することができる。
なお、口腔ケア製品とは、健全な口腔、歯、及び歯肉を促進するか、息を爽やかにするか、又は口腔疾患を予防若しくは治療するために使用される、口腔内をケアする製品をいう。
また、本実施形態において挙げた、口腔用組成物を含むもしくは口腔用組成物からなる口腔ケア製品又は食品を構成することもできる。これにより、本発明の効果を有する口腔ケア製品又は食品を実現することができる。
More specifically, oral compositions include toothpastes, liquid toothpastes, liquid toothpastes, dentifrices such as Junsei toothpastes, mouthwashes including mouthwashes and mouthwashes, and mouthsprays which are examples of oral sprays. , oral pasta, mouth fresheners, gargles, dental rinses, oral moisturizers, denture stabilizers, denture lubricants, artificial saliva, ointments, patches, toothpaste sheets/naps, tablets, pastilles, tablets, etc. It can be prepared into various dosage forms such as tablets, capsules, gummies, candies, granules, chewing gum, gel foods, drinks, and preserved foods. That is, the oral composition according to the present embodiment can be in the form of an oral care product, a food product, a food product, or the like. In particular, it is suitably prepared as a dentifrice, a mouthwash, a tablet, a gummy, a candy, a gel-like food, especially as a dentifrice or a mouthwash. Note that tablets, gummies, candies, and the like can be preferably used because they remain in the oral cavity for a relatively long time in terms of imparting antibacterial effects.
Oral care products refer to oral care products used to promote a healthy mouth, teeth, and gums, to freshen breath, or to prevent or treat oral diseases. .
Moreover, it is also possible to constitute an oral care product or food containing or consisting of the oral composition mentioned in this embodiment. Thereby, an oral care product or food having the effects of the present invention can be realized.
また、このような種々の剤型の製剤を調製するには、本発明の菌体や培養物の作用を妨げない範囲で、他の薬学的に許容される賦形剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝剤、保存剤、香料、被膜剤、担体、希釈剤等を適宜組み合わせて用いることができる。 In addition, in order to prepare such various dosage forms, other pharmaceutically acceptable excipients, binders, and fillers may be added to the extent that they do not interfere with the action of the bacterial cells or cultures of the present invention. , a disintegrant, a surfactant, a lubricant, a dispersant, a buffer, a preservative, a fragrance, a coating agent, a carrier, a diluent, and the like can be used in appropriate combinations.
上記口腔用組成物において、ＫＯ３株の菌体若しくは菌体培養物又はこれらの抽出物の組成物全体に対する配合率としては、病原性細菌を抗菌するために０．００１～１０％（重量％、以下同様）が好ましく、より好ましくは０．０１～５．０％である。
また、上記口腔用組成物の剤型が、例えば液体の場合には、ＫＯ３株の濃度を０．００１ｇ／ｍｌ～０．０２５ｇ／ｍｌとすることが好ましい。
In the above-mentioned oral composition, the proportion of the KO3 strain bacterial cells or bacterial cell culture or their extracts in the entire composition is 0.001 to 10% (wt%, (same below) is preferred, and more preferably 0.01 to 5.0%.
Furthermore, when the dosage form of the oral composition is, for example, a liquid, the concentration of the KO3 strain is preferably 0.001 g/ml to 0.025 g/ml.
本発明では、ＫＯ３株の菌体若しくは菌体培養物又はこれらの抽出物を配合する場合、その配合率が上記範囲内であると、より優れた選択的抗菌効果を付与することができる。なお、前記ＫＯ３株の菌体若しくは菌体培養物又はこれらの抽出物の配合率が高いほど、抗菌効果が向上するが、配合率が高すぎると有用な常在菌を減少させることになる。 In the present invention, when the bacterial cells of the KO3 strain, the bacterial cell culture, or their extracts are blended, a superior selective antibacterial effect can be imparted if the blending ratio is within the above range. Incidentally, the higher the blending ratio of the bacterial cells of the KO3 strain, the bacterial cell culture, or their extracts, the better the antibacterial effect will be, but if the blending ratio is too high, useful resident bacteria will be reduced.
また、口腔用組成物には、上記成分に加えて、本発明の効果を妨げない範囲において、剤型に応じた適宜なその他の公知成分を必要に応じて配合し、通常の方法で調製できる。 In addition to the above-mentioned components, the oral composition can be prepared by a conventional method by adding other known components suitable for the dosage form as necessary, within a range that does not impede the effects of the present invention. .
歯磨剤には、例えば、研磨剤、粘稠剤、粘結剤、界面活性剤、更に必要によって甘味剤、着色剤、防腐剤、保湿剤、香料、有効成分等を配合できる。洗口剤には、粘稠剤、粘結剤、界面活性剤、更に必要によって甘味剤、着色剤、防腐剤、香料、有効成分等を配合できる。錠剤には、ソルビトール、マルチトール等の糖アルコール、セルロース、乳糖、デキストリン等の賦形剤、微粒二酸化ケイ素、酸味料、甘味剤、着色剤、乳化剤、増粘剤、ゲル化剤、果汁、香辛料、有効成分等を配合できる。グミには、グリセリン、ゼラチン等の増粘剤やゲル化剤、糖類、酸味料、甘味剤、着色剤、乳化剤、果汁、有効成分等を配合できる。チューインガムには、ガムベース、食用ガム質等の結合剤、甘味剤、着色剤、酸味料、保存料、光沢剤、香料、有効成分等を配合でき、必要に応じて糖衣で被覆してもよい。 The dentifrice may contain, for example, an abrasive, a thickener, a binder, a surfactant, and if necessary, a sweetener, a coloring agent, a preservative, a humectant, a fragrance, an active ingredient, and the like. The mouthwash may contain a thickening agent, a binder, a surfactant, and if necessary, a sweetener, a coloring agent, a preservative, a fragrance, an active ingredient, and the like. Tablets contain sugar alcohols such as sorbitol and maltitol, excipients such as cellulose, lactose, and dextrin, fine silicon dioxide, acidulants, sweeteners, colorants, emulsifiers, thickeners, gelling agents, fruit juice, and spices. , active ingredients, etc. can be blended. Gummies can contain thickeners and gelling agents such as glycerin and gelatin, sugars, acidulants, sweeteners, colorants, emulsifiers, fruit juice, active ingredients, and the like. The chewing gum may contain a gum base, a binder such as an edible gum, a sweetening agent, a coloring agent, an acidulant, a preservative, a brightening agent, a flavoring agent, an active ingredient, etc., and may be coated with a sugar coating if necessary.
歯磨剤に用いられる研磨剤としては、例えば、シリカ系研磨剤、リン酸カルシウム系研磨剤、炭酸カルシウム系研磨剤などが挙げられ、その配合量は、通常、練歯磨では２～５０％、液状歯磨では０～３０％である。 Examples of abrasives used in toothpastes include silica-based abrasives, calcium phosphate-based abrasives, and calcium carbonate-based abrasives, and the amount of these is usually 2 to 50% in toothpastes and 2% to 50% in liquid toothpastes. It is 0-30%.
粘稠剤としては、例えば、ソルビトール、キシリトール等の糖アルコール、グリセリン、プロピレングリコール等の多価アルコールが挙げられる。その配合量は、通常、５～５０％である。 Examples of the thickening agent include sugar alcohols such as sorbitol and xylitol, and polyhydric alcohols such as glycerin and propylene glycol. Its blending amount is usually 5 to 50%.
粘結剤としては、例えば、カルボキシメチルセルロースナトリウム等のセルロース誘導体、キサンタンガム等のガム類、ゲル化性シリカ、ゲル化性アルミニウムシリカなどの有機又は無機粘結剤を配合できる。その配合量は、通常、０．５～１０％である。 As the binder, for example, cellulose derivatives such as sodium carboxymethylcellulose, gums such as xanthan gum, organic or inorganic binders such as gelling silica, gelling aluminum silica, etc. can be blended. Its blending amount is usually 0.5 to 10%.
また、界面活性剤としては、例えば、口腔用組成物に一般的に用いられるアニオン性界面活性剤、ノニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤を配合できる。アニオン性界面活性剤としては、ラウリル硫酸ナトリウム等のアルキル硫酸塩、Ｎ－アシルサルコシン酸塩などが挙げられる。ノニオン性界面活性剤としては、糖脂肪酸エステル、糖アルコール脂肪酸エステル、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油等のポリオキシエチレン脂肪酸エステル、ポリオキシエチレン高級アルコールエーテル、脂肪酸アルカノールアミドなどが挙げられる。カチオン性界面活性剤としては、アルキルアンモニウム塩等、両性界面活性剤としては、ベタイン系やイミダゾリン系のものが挙げられる。界面活性剤の配合量は、通常、０～１０％、特に０．０１～５％である。 Furthermore, as the surfactant, for example, anionic surfactants, nonionic surfactants, cationic surfactants, and amphoteric surfactants commonly used in oral compositions can be blended. Examples of the anionic surfactant include alkyl sulfates such as sodium lauryl sulfate, N-acyl sarcosinates, and the like. Examples of nonionic surfactants include sugar fatty acid esters, sugar alcohol fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene fatty acid esters such as polyoxyethylene hydrogenated castor oil, polyoxyethylene higher alcohol ethers, fatty acid alkanolamides, etc. can be mentioned. Examples of cationic surfactants include alkylammonium salts, and examples of amphoteric surfactants include betaine and imidazoline surfactants. The amount of surfactant added is usually 0 to 10%, particularly 0.01 to 5%.
甘味剤としては、例えば、キシリトール、スクラロース、サッカリンナトリウム等が挙げられる。着色剤としては、赤色２号、青色１号、黄色４号等が、防腐剤としては、パラオキシ安息香酸エステル等が挙げられる。 Examples of sweeteners include xylitol, sucralose, and sodium saccharin. Examples of the coloring agent include Red No. 2, Blue No. 1, Yellow No. 4, etc., and examples of the preservative include paraoxybenzoic acid ester.
香料または着香剤としては、例えば、ペパーミント油、スペアミント油、アニス油、ユーカリ油、ケイヒ油、ウイキョウ油、チョウジ油（丁字油）、ウィンターグリーン油、カシア油、クローブ油、タイム油、セージ油、レモン油、オレンジ油、ハッカ油、カルダモン油、コリアンダー油、マンダリン油、ライム油、ラベンダー油、ローズマリー油、ローレル油、カモミル油、キャラウェイ油、マジョラム油、ベイ油、レモングラス油、オリガナム油、パインニードル油、ネロリ油、ローズ油、ジャスミン油、グレープフルーツ油、スウィーティー油、柚油、イリスコンクリート、アブソリュートペパーミント、アブソリュートローズ、オレンジフラワー等の天然香料、及びこれら天然香料の加工処理（前溜部カット、後溜部カット、分留、液液抽出、エッセンス化、粉末香料化等）した香料、及び、メントール、カルボン、アネトール、シネオール、サリチル酸メチル、シンナミックアルデヒド、オイゲノール、３－ｌ－メントキシプロパン－１，２－ジオール、チモール、リナロール、リナリールアセテート、リモネン、メントン、メンチルアセテート、Ｎ－置換－パラメンタン－３－カルボキサミド、ピネン、オクチルアルデヒド、シトラール、プレゴン、カルビールアセテート、アニスアルデヒド、エチルアセテート、エチルブチレート、アリルシクロヘキサンプロピオネート、メチルアンスラニレート、エチルメチルフェニルグリシデート、バニリン、ウンデカラクトン、ヘキサナール、ブタノール、イソアミルアルコール、ヘキセノール、ジメチルサルファイド、シクロテン、フルフラール、トリメチルピラジン、エチルラクテート、エチルチオアセテート等の単品香料、更に、ストロベリーフレーバー、アップルフレーバー、アップルミントフレーバー、バナナフレーバー、パイナップルフレーバー、グレープフレーバー、マンゴーフレーバー、バターフレーバー、ミルクフレーバー、フルーツミックスフレーバー、トロピカルフルーツフレーバー等の調合香料等が挙げられ、口腔用組成物に用いられる公知の香料素材を使用できる。
これら香料の配合量は、通常、歯磨剤、洗口剤では０．０００１～１％であり、また、錠剤、グミ、チューインガムでは０．００１～５０％であり、また、上記香料素材を使用した賦香用香料は、組成中に０．１～１０％使用するのが好ましい。
Flavoring or flavoring agents include, for example, peppermint oil, spearmint oil, anise oil, eucalyptus oil, cinnamon oil, fennel oil, clove oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage oil. , lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, lime oil, lavender oil, rosemary oil, laurel oil, chamomile oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum. natural fragrances such as oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie oil, yuzu oil, iris concrete, absolute peppermint, absolute rose, orange flower, and processing of these natural fragrances (pre-distilled). Fragrances such as partial cut, rear distillation cut, fractional distillation, liquid-liquid extraction, essence, powder fragrance, etc.), and menthol, carvone, anethole, cineole, methyl salicylate, cinnamic aldehyde, eugenol, 3-l-menth. Xypropane-1,2-diol, thymol, linalool, linaryl acetate, limonene, menthone, menthyl acetate, N-substituted-paramenthane-3-carboxamide, pinene, octylaldehyde, citral, pulegone, carbyl acetate, anisaldehyde, Ethyl acetate, ethyl butyrate, allyl cyclohexane propionate, methyl anthranilate, ethyl methyl phenyl glycidate, vanillin, undecalactone, hexanal, butanol, isoamyl alcohol, hexenol, dimethyl sulfide, cyclotene, furfural, trimethyl pyrazine, ethyl Single flavorings such as lactate and ethylthioacetate, as well as combinations of strawberry flavor, apple flavor, apple mint flavor, banana flavor, pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, mixed fruit flavor, tropical fruit flavor, etc. Examples include perfumes, and known perfume materials used in oral compositions can be used.
The amount of these fragrances is usually 0.0001 to 1% in toothpastes and mouthwashes, and 0.001 to 50% in tablets, gummies, and chewing gum. It is preferable to use 0.1 to 10% of the fragrance in the composition.
有効成分としては、口腔用組成物に通常配合される公知のものを本発明の効果を妨げない範囲で配合できる。有効成分としては、イソプロピルメチルフェノール等の非イオン性殺菌剤、塩化セチルピリジニウム等のカチオン性殺菌剤、トラネキサム酸、イプシロンアミノカプロン酸等の抗炎症剤、デキストラナーゼ等の酵素、フッ化ナトリウム、モノフルオロリン酸ナトリウム等のフッ化物、水溶性リン酸化合物、銅化合物、硝酸カリウム、乳酸アルミニウム、各種ビタミン類、植物抽出物などが挙げられる。なお、上記有効成分の配合量は、本発明の選択的抗菌効果を妨げない範囲で設定される。 As the active ingredient, any known active ingredient that is commonly blended into oral compositions can be blended within a range that does not impede the effects of the present invention. Active ingredients include non-ionic disinfectants such as isopropyl methylphenol, cationic disinfectants such as cetylpyridinium chloride, anti-inflammatory agents such as tranexamic acid and epsilon aminocaproic acid, enzymes such as dextranase, sodium fluoride, monomers, etc. Examples include fluorides such as sodium fluorophosphate, water-soluble phosphoric acid compounds, copper compounds, potassium nitrate, aluminum lactate, various vitamins, and plant extracts. The amount of the above-mentioned active ingredient is set within a range that does not interfere with the selective antibacterial effect of the present invention.
なお、本発明の口腔用組成物においては、歯周病原性細菌と共に非病原性細菌をも殺菌する非選択的殺菌剤の配合は制限することが好ましい。前記非選択的殺菌剤は、従来から広く口腔用製剤に使用されている殺菌剤に多く見られ、例えば塩化セチルピリジニウム、塩化ベンゼトニウム、塩化ベンザルコニウム等のカチオン性殺菌剤が挙げられる。また、イソプロピルメチルフェノール等の非イオン性殺菌剤なども挙げられる。 In addition, in the oral composition of the present invention, it is preferable to limit the amount of non-selective sterilizers that sterilize non-pathogenic bacteria as well as periodontal pathogenic bacteria. The non-selective disinfectants are commonly found in disinfectants that have been widely used in oral preparations, and examples include cationic disinfectants such as cetylpyridinium chloride, benzethonium chloride, and benzalkonium chloride. Also included are nonionic disinfectants such as isopropylmethylphenol.
これら非選択的殺菌剤は、本発明の口腔用組成物が選択的抗菌効果を有する範囲で配合することができるが、配合する場合は組成物全体の０．１％以下、特に０．０５％以下が好ましく、配合しないことが最も好ましい。これらの非選択的殺菌剤は、病原性の歯周病原性細菌と共に非病原性の口腔内常在菌をも殺菌してしまう、非選択的な殺菌作用を奏するため、これら殺菌剤が配合されていると、口腔内の菌バランスが崩れて口腔内常在菌叢が制御できなくなり、菌交代症の可能性が生じてくる場合がある。従って、本発明においては、上記非選択的殺菌剤が配合されていないほうが、選択的抗菌効果による口腔内常在菌叢のバランス制御にはより好ましい。
以下に、実施例及び抗菌力の試験結果を示し、本発明についてより詳細に説明する。
These non-selective bactericidal agents can be blended within the range in which the oral composition of the present invention has a selective antibacterial effect, but when blended, they account for 0.1% or less, particularly 0.05% of the total composition. The following are preferred, and it is most preferred not to include it. These non-selective bactericidal agents have a non-selective bactericidal effect that kills non-pathogenic oral bacteria as well as pathogenic periodontal pathogenic bacteria, so these bactericidal agents are combined. If this occurs, the bacterial balance in the oral cavity may be disrupted, and the normal oral flora may become uncontrollable, leading to the possibility of bacterial replacement. Therefore, in the present invention, it is more preferable that the above-mentioned non-selective bactericidal agent is not blended in order to control the balance of the oral flora due to the selective antibacterial effect.
Examples and antibacterial activity test results are shown below, and the present invention will be explained in more detail.
以下、試験例などにより本発明をさらに詳しく説明するが、本発明はこれらによりなんら限定されるものではない。また、特に断らない限り「％」は重量％を意味する。 Hereinafter, the present invention will be explained in more detail using test examples and the like, but the present invention is not limited to these in any way. Further, unless otherwise specified, "%" means % by weight.
（菌体の調製）
ＭＲＳ培地（Ｄｉｆｃｏ社）を１２１℃で２０分間滅菌した後、ラクトバチルス・ラムノーサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）ＫＯ３株（ＮＩＴＥ ＢＰ－７７１）を接種し、３７℃で、４８時間大気下で培養した後、蒸留水・超純水・緩衝液などで洗浄後、菌体を調製した。
(Preparation of bacterial cells)
After sterilizing MRS medium (Difco) at 121°C for 20 minutes, Lactobacillus rhamnosus KO3 strain (NITE BP-771) was inoculated, cultured at 37°C for 48 hours in the atmosphere, and then distilled. After washing with water, ultrapure water, buffer, etc., bacterial cells were prepared.
以上に示されるＫＯ３株は、公知の手法によって調整することができ、その方法を限定するものではない。 The KO3 strain shown above can be prepared by a known method, and the method is not limited.
＜口腔内の非病原性細菌に対するＫＯ３株の抗菌力試験＞
口腔内の非病原性細菌であるストレプトコッカス ミティス及びストレプトコッカス オラリスの２種の各菌に対するＫＯ３株の抗菌力を試験する。
<Antibacterial activity test of KO3 strain against non-pathogenic bacteria in the oral cavity>
The antibacterial activity of strain KO3 against two non-pathogenic bacteria in the oral cavity, Streptococcus mitis and Streptococcus oralis, will be tested.
［試験（１）］
ＫＯ３株の抗菌力を評価した。なお、対照としてＫＯ３株を配合しない精製水を用いた。
[Test (1)]
The antibacterial activity of the KO3 strain was evaluated. Note that purified water without the KO3 strain was used as a control.
１．検体
本発明に係る口腔用組成物の一例としてＫＯ３株を２．５％の配合率で配合した評価用のＫＯ３株含有洗口液（基材：精製水）を調整して、市販されている洗口液である市販品Ａ、Ｂと合わせて抗菌力試験を行った。
検体１）２．５％ＫＯ３株含有株洗口液（ノンアルコール系、基材：水、殺菌剤無し）
検体２）市販品Ａ（ノンアルコール系、薬用成分として塩化セチルピリジニウム（殺菌剤ＣＰＣ）配合）
検体３）市販品Ｂ（ノンアルコール系、薬用成分として１，８‐シネオール、塩化亜鉛等配合）
２．試験概要
検体に試験菌液を接種後（以下、「試験液」という。）、所定時間後に試験液中の生菌数を測定した。また、あらかじめ予備試験（中和条件の確認）を行い、検体の影響を受けずに生菌数を測定できる条件を確認した。
３．試験条件
ａ）試験菌として、以下の非病原性細菌の菌種を用いた。
（１）ストレプトコッカス ミティス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｍｉｔｉｓ ＮＢＲＣ １０６０７１）
（２）ストレプトコッカス オラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｏｒａｌｉｓ ＪＣＭ １２９９７）
ｂ）試験菌液：試験菌をＴｒｙｐｔｉｃａｓｅ ｓｏｙ ａｇａｒ（ＢＢＬ）で３７℃±１℃、１８～２４時間後嫌気培養した後、精製水に浮遊させ、菌数が１０８～１０９／ｍＬとなるように調整した。
ｃ）試験液：検体１０ｍＬに試験菌液０．１ｍＬを接種
ｄ）保存条件：３０秒、３分（室温）
ｅ）対照：精製水
ｆ）中和条件：ＳＣＤＬＰ培地（日本製薬株式会社）で１０倍希釈（なお、試験菌がストレプトコッカス ミティスの場合の検体２は１００倍希釈）
ｇ）生菌数測定：Ｔｒｙｐｔｉｃａｓｅ ｓｏｙ ａｇａｒ、混釈平板培養法
４．試験結果
試験菌としてストレプトコッカス ミティス及びストレプトコッカス オラリスを用いたそれぞれの試験結果を表１、表２に示す。なお、試験液をＳＣＤＬＰ培地で１０倍（試験菌がストレプトコッカス ミティスの場合の検体２は１００倍希釈）に希釈することにより、検体の影響を受けずに生菌数の測定ができることを予備試験により確認した。
なお、以下の表１、表２の「対象」における検体１）、検体２）、検体３）とは、それぞれ上述した２．５％ＫＯ３株含有株洗口液、市販品Ａ、市販品Ｂのことである。
1. Specimen As an example of the oral composition according to the present invention, a mouthwash containing the KO3 strain for evaluation (base material: purified water) containing the KO3 strain at a blending rate of 2.5% was prepared and commercially available. An antibacterial activity test was conducted with commercially available mouthwashes A and B.
Sample 1) Strain mouthwash containing 2.5% KO3 strain (non-alcoholic, base material: water, no disinfectant)
Sample 2) Commercial product A (non-alcoholic, containing cetylpyridinium chloride (bactericide CPC) as a medicinal ingredient)
Sample 3) Commercial product B (non-alcoholic, contains medicinal ingredients such as 1,8-cineole and zinc chloride)
2. Test Overview After inoculating the specimen with the test bacterial solution (hereinafter referred to as the "test solution"), the number of viable bacteria in the test solution was measured after a predetermined period of time. In addition, a preliminary test (confirmation of neutralization conditions) was conducted in advance to confirm the conditions under which the number of viable bacteria could be measured without being affected by the sample.
3. Test conditions a) The following non-pathogenic bacterial species were used as test bacteria.
(1) Streptococcus mitis (Streptococcus mitis NBRC 106071)
(2) Streptococcus oralis (Streptococcus oralis JCM 12997)
b) Test bacteria solution: After culturing the test bacteria anaerobically in trypticase soy agar (BBL) at 37°C ± 1°C for 18 to 24 hours, suspend it in purified water until the number of bacteria reaches 10 8 to 10 9 /mL. I adjusted it as follows.
c) Test solution: Inoculate 10 mL of sample with 0.1 mL of test bacterial solution d) Storage conditions: 30 seconds, 3 minutes (room temperature)
e) Control: Purified water f) Neutralization conditions: 10-fold dilution with SCDLP medium (Nippon Pharmaceutical Co., Ltd.) (In addition, when the test bacteria is Streptococcus mitis, sample 2 is diluted 100-fold)
g) Measurement of viable bacteria count: Trypticase soy agar, pour plate culture method 4. Test Results Tables 1 and 2 show the test results using Streptococcus mitis and Streptococcus oralis as test bacteria. Preliminary tests have shown that by diluting the test solution 10 times with SCDLP medium (100 times dilution for sample 2 when the test bacterium is Streptococcus mitis), the number of viable bacteria can be measured without being affected by the sample. confirmed.
In addition, sample 1), sample 2), and sample 3) in "Target" in Tables 1 and 2 below refer to the above-mentioned strain mouthwash containing 2.5% KO3 strain, commercial product A, and commercial product B, respectively. It is about.
表１の結果に基づく棒グラフを図１に示す。図１（ａ）では、各検体における保存時間（３０秒、３分）毎の生菌数（対数表示）を比較して表示した。図１（ｂ）では、試験開始時を１００％とし、各検体における保存時間毎の生菌数の変化率を比較して表示した。ここで、図１においては、開始時において、４本の棒グラフを示しているが、左から右に順に、２．５％ＫＯ３株含有洗口液、市販品Ａ、市販品Ｂ、対照に関する試験結果である。 A bar graph based on the results in Table 1 is shown in FIG. In FIG. 1(a), the number of viable bacteria (logarithm display) for each specimen at each storage time (30 seconds, 3 minutes) is compared and displayed. In FIG. 1(b), the time at the start of the test is set as 100%, and the rate of change in the number of viable bacteria for each specimen at each storage time is compared and displayed. Here, in FIG. 1, four bar graphs are shown at the beginning, and in order from left to right, tests regarding 2.5% KO3 strain-containing mouthwash, commercial product A, commercial product B, and control. This is the result.
表２の結果に基づく棒グラフを図２に示す。図２（ａ）では、各検体における保存時間（３０秒、３分）毎の生菌数（対数表示）を比較して表示した。図２（ｂ）では、試験開始時を１００％とし、各検体における保存時間毎の生菌数の変化率を比較して表示した。ここで、図２においては、開始時において、４本の棒グラフを示しているが、左から右に順に、２．５％ＫＯ３株含有洗口液、市販品Ａ、市販品Ｂ、対照に関する試験結果である。 A bar graph based on the results in Table 2 is shown in FIG. In FIG. 2(a), the number of viable bacteria (logarithm display) for each specimen at each storage time (30 seconds, 3 minutes) is compared and displayed. In FIG. 2(b), the time at the start of the test is set as 100%, and the rate of change in the number of viable bacteria for each specimen at each storage time is compared and displayed. Here, in FIG. 2, four bar graphs are shown at the beginning, and in order from left to right, the test for mouthwash containing 2.5% KO3 strain, commercial product A, commercial product B, and control. This is the result.
表１（図１）、表２（図２）においては、保存時間毎において生菌数が多いほど有用な常在菌であるストレプトコッカス ミティスやストレプトコッカス オラリスが残存していることを表しており、好ましい結果となる。また、本実施例では口腔用組成物の一例として洗口液を試験したものであるが、洗口液は、一般的に短時間（例えば、３０秒程度）で口腔内全体に行き渡らしてから口腔外に吐き出すようにして使用される。そのため、例えば、開始後３０秒後に着目すると、表１及び表２では市販品Ａ、市販品Ｂはすでにストレプトコッカス ミティス及びストレプトコッカス オラリスが検出できないレベルにまで減少しており、有用な常在菌がほぼ残存していないが、本発明に係る２．５％ＫＯ３株含有株洗口液では、まだ多くの有用な常在菌が残存しているが確認できた（３０秒後の生菌率において、ストレプトコッカス ミティスが８３％、ストレプトコッカス オラリスが７５％）。
このことから、本発明における選択的抗菌効果は、本試験方法において、評価に用いた非病原性細菌に対して、３０秒時に生菌率が０．７以上となる効果である。
In Table 1 (Figure 1) and Table 2 (Figure 2), the higher the number of viable bacteria at each storage time, the more useful resident bacteria Streptococcus mitis and Streptococcus oralis remain, which is preferable. result. In addition, in this example, a mouthwash was tested as an example of an oral composition, but mouthwashes are generally spread throughout the oral cavity in a short period of time (for example, about 30 seconds) and then It is used by spitting it out of the mouth. Therefore, for example, if we focus on 30 seconds after the start, in Tables 1 and 2, Streptococcus mitis and Streptococcus oralis have already decreased to an undetectable level in Commercial Product A and Commercial Product B, and almost all useful resident bacteria are present. However, in the strain mouthwash containing 2.5% KO3 strain according to the present invention, it was confirmed that many useful indigenous bacteria still remained (in the viable bacteria rate after 30 seconds, 83% for Streptococcus mitis and 75% for Streptococcus oralis).
From this, the selective antibacterial effect in the present invention is an effect in which the viable bacteria rate is 0.7 or more at 30 seconds with respect to the non-pathogenic bacteria used for evaluation in this test method.
［試験（２）］
上述した抗菌力試験方法に基づいて、検体として２．５％ＫＯ３株含有株洗口液と、市販品Ａを用いて、かつ保存条件を１分、５分、１０分（室温）として抗菌力試験を行った結果を図３に示す。図３のグラフより明らかなように、本発明に係る２．５％ＫＯ３株含有株洗口液の場合は、１０分経過後においても有用な常在菌であるストレプトコッカス ミティスやストレプトコッカス オラリスが残存している。一方、市販品Ａにおいては１分後においてすでに残存していない。すなわち、２．５％ＫＯ３株含有株洗口液においては有用常在菌に対して抗菌作用が緩和されていることが確認された。それに対して、市販品Ａにおいては殺菌剤である塩化セチルピリジニウムの影響により歯周病等の原因菌だけでなく有用常在菌までも殺菌してしまったと推察される。
[Test (2)]
Based on the above-mentioned antibacterial activity test method, antibacterial activity was determined using a strain mouthwash containing 2.5% KO3 strain and commercially available product A as specimens, and under storage conditions of 1 minute, 5 minutes, and 10 minutes (room temperature). The results of the test are shown in Figure 3. As is clear from the graph in Figure 3, in the case of the strain mouthwash containing 2.5% KO3 strain according to the present invention, useful indigenous bacteria such as Streptococcus mitis and Streptococcus oralis remain even after 10 minutes. ing. On the other hand, commercially available product A does not remain after 1 minute. That is, it was confirmed that the antibacterial effect against useful indigenous bacteria was alleviated in the strain mouthwash containing 2.5% KO3 strain. On the other hand, in commercially available product A, it is presumed that not only the causative bacteria of periodontal disease, etc. but also useful resident bacteria were sterilized due to the effect of cetylpyridinium chloride, which is a bactericide.
［試験（３）］
上述した抗菌力試験方法に基づいて、本発明に係る口腔用組成物の一例としてＫＯ３株を０．６％、１．２５％、２．５％の各配合率で配合した評価用のＫＯ３株含有洗口液（主成分：精製水）を調製して、かつ保存条件を１分、５分、１０分（室温）として抗菌力の濃度依存性試験を行った。試験結果を図４に示す。ここで、図４においては、各時間において、４本の棒グラフを示しているが、左から右に順に、２．５％ＫＯ３株含有洗口液、１．２５％ＫＯ３株含有洗口液、０．６％ＫＯ３株含有洗口液、対照に関する試験結果である。図４に示す試験結果により、ストレプトコッカス ミティスに対してはＫＯ３株の濃度依存性があり、ＫＯ３株の配合濃度が高いほど、生菌数が減少していることが確認できた。一方、ストレプトコッカス オラリスに対してはＫＯ３株の濃度依存性が確認できなかった。このように、ＫＯ３株においては、上述したようにう蝕菌や歯周病菌等の病原性細菌に対して優れた増殖抑制効果を有するが、非病原性細菌で有用な常在菌であるストレプトコッカス ミティスに対しては生菌数を減少させてしまうことが確認できた。このことを考慮すると、ＫＯ３株の口腔用組成物全体に対する配合率は０．０１～５．０重量％が好ましく、より好ましくは０．１～４．０重量％、更に好ましくは０．５～３．０重量％である。こうして、ＫＯ３株は所定の処方において口腔用組成物に含有させることで、選択的抗菌剤として作用し、口腔常在菌調整作用を有することが確認できた。
[Test (3)]
Based on the above-mentioned antibacterial activity test method, the KO3 strain for evaluation was blended with each blending ratio of 0.6%, 1.25%, and 2.5% as an example of the oral composition according to the present invention. A concentration-dependent test of antibacterial activity was conducted by preparing a mouthwash containing the following ingredients (main component: purified water) and storing them for 1 minute, 5 minutes, and 10 minutes (room temperature). The test results are shown in Figure 4. Here, in FIG. 4, four bar graphs are shown at each time, and from left to right, mouthwash containing 2.5% KO3 strain, mouthwash containing 1.25% KO3 strain, These are test results regarding a control mouthwash containing 0.6% KO3 strain. From the test results shown in FIG. 4, it was confirmed that Streptococcus mitis was dependent on the concentration of the KO3 strain, and the higher the concentration of the KO3 strain, the lower the number of viable bacteria. On the other hand, no concentration dependence of the KO3 strain on Streptococcus oralis could be confirmed. In this way, the KO3 strain has an excellent growth-inhibiting effect against pathogenic bacteria such as cariogenic bacteria and periodontal disease bacteria as described above, but it has an excellent growth-inhibiting effect against pathogenic bacteria such as cariogenic bacteria and periodontal disease bacteria, but it also inhibits the growth of Streptococcus, which is a useful non-pathogenic bacteria. It was confirmed that the number of viable bacteria against Mitis was reduced. Considering this, the blending ratio of the KO3 strain to the entire oral composition is preferably 0.01 to 5.0% by weight, more preferably 0.1 to 4.0% by weight, even more preferably 0.5 to 5.0% by weight. It is 3.0% by weight. In this way, it was confirmed that the KO3 strain acts as a selective antibacterial agent and has an effect of regulating oral bacteria when included in an oral composition in a predetermined formulation.
試験（１）、（２）、（３）の結果について考察すると、本発明に係るＫＯ３株含有洗口液と市販品Ａ、Ｂと比較すると、例えば、図１に示すように、２．５％ＫＯ３株水溶液では有用常在菌の生菌数が維持されており、当該有用常在菌に悪影響を及ぼさないことが確認された。これにより、口膣内での使用を想定した口腔用組成物としてのＫＯ３株の優位性が確認された。すなわち、ＫＯ３株は有用常在菌の生育阻害が緩和されているのに対して、市販品Ａ、Ｂは配合されている殺菌剤の影響によって顕著に有用常在菌の生育を阻害していると考えられる。
以上により、ＫＯ３株含有洗口液は、市販品Ａ、Ｂと比較して、有用常在菌であるストレプトコッカス ミティスやストレプトコッカス オラリスを残存させることができることが確認できた。
Considering the results of tests (1), (2), and (3), when comparing the mouthwash containing the KO3 strain according to the present invention with commercially available products A and B, for example, as shown in FIG. It was confirmed that the viable count of useful indigenous bacteria was maintained in the aqueous solution of %KO3 strain, and that it did not have an adverse effect on the useful indigenous bacteria. This confirmed the superiority of the KO3 strain as an oral composition intended for oral or vaginal use. In other words, while the KO3 strain has less inhibition of the growth of useful indigenous bacteria, commercial products A and B significantly inhibit the growth of useful indigenous bacteria due to the effects of the fungicides contained in them. it is conceivable that.
As a result of the above, it was confirmed that the mouthwash containing the KO3 strain was able to retain useful indigenous bacteria such as Streptococcus mitis and Streptococcus oralis compared to commercially available products A and B.
また、本発明に係るＫＯ３株含有洗口液は、上述したように選択的抗菌作用を有し、例えば、口膣内において病原性細菌等の原因菌に対しては抗菌作用が効果的に働くとともに、口腔内常在菌（本実施形態では、ストレプトコッカス ミティス、ストレプトコッカス オラリス）に対しては抗菌作用が緩和される。このように、本発明に係るＫＯ３株含有洗口液は口膣内の有用な常在菌を死滅させることなく安定して存在させて、常在菌の病原性細菌に対する耐性を維持することができる。 In addition, the mouthwash containing the KO3 strain according to the present invention has a selective antibacterial effect as described above, and for example, the antibacterial effect effectively acts against causative bacteria such as pathogenic bacteria in the oral cavity. At the same time, the antibacterial action against bacteria resident in the oral cavity (in this embodiment, Streptococcus mitis and Streptococcus oralis) is alleviated. As described above, the mouthwash containing the KO3 strain according to the present invention can stably exist the useful indigenous bacteria in the oral cavity without killing them, and can maintain the resistance of the indigenous bacteria to pathogenic bacteria. can.
また、本発明に係るＫＯ３株は、口膣内常在菌に影響を与えず、常在菌により病原性微生物の侵入や増殖を抑制させるプロバイオティクスの概念を達成する素材として提供することができる。 In addition, the KO3 strain according to the present invention can be provided as a material that achieves the concept of probiotics that does not affect the resident bacteria in the oral cavity and suppresses the invasion and proliferation of pathogenic microorganisms by the resident bacteria. can.
本発明の口腔用組成物には、添加剤としては、本発明の効果を阻害しない範囲でその形態に応じた、基剤（水、アルコール等）、潤滑材、清掃剤（デキストリン等）、ｐＨ調整剤（クエン酸Ｎａ等）、清掃剤、香味剤、香料、甘味料（キシリトール、スクラロース等）、可溶可剤、保存剤（メチルパラベン、エチルパラベン、プロピルパラベン等）、保湿剤、乳化剤、分散剤、増粘剤、酸化防止剤、紫外線吸収剤等からなる群から選ばれる１種又は２種以上のものを加えることができる。 The oral composition of the present invention may include a base (water, alcohol, etc.), lubricant, cleaning agent (dextrin, etc.), pH Conditioners (Na citrate, etc.), cleaning agents, flavoring agents, fragrances, sweeteners (xylitol, sucralose, etc.), solubilizers, preservatives (methylparaben, ethylparaben, propylparaben, etc.), humectants, emulsifiers, dispersants One or more selected from the group consisting of additives, thickeners, antioxidants, ultraviolet absorbers, etc. can be added.
以上の如く、本発明によれば、口腔内における非病原性細菌を残存させるとともに、選択的に口腔内の病原性細菌に対して抗菌効果を奏するようにして口腔内の常在菌のバランスを良好に保つように調整可能な、優れた選択的抗菌効果を奏する。 As described above, according to the present invention, non-pathogenic bacteria in the oral cavity remain and the balance of resident bacteria in the oral cavity is maintained by selectively exerting an antibacterial effect on pathogenic bacteria in the oral cavity. Excellent selective antibacterial effect that can be adjusted to maintain good performance.
Claims (4)
前記ラクトバチルス・ラムノーサスＫＯ３株の組成物全体に対する配合率が０．６～２．５重量％であり、
口腔内の非病原性細菌の生育を抑制することなく病原性細菌の生育を抑制するように選択的に作用する上記口腔常在菌調整剤を含む口腔用組成物であって、
前記病原性細菌が、歯周病原性細菌であるポルフィロモナス ジンジバリス及び／又はプレボテラ インターメディアであり、
前記非病原性細菌が、ストレプトコッカス ミティス及びストレプトコッカス オラリスから選ばれるミティスグループの連鎖球菌であり、
前記歯周病原性細菌と共に前記非病原性細菌を殺菌する非選択的な殺菌作用を奏する非選択的殺菌剤を含まない、口腔内の非病原性細菌の生育を抑制することなく病原性細菌の生育を抑制するように選択的に作用する口腔用組成物。 Contains Lactobacillus rhamnosus KO3 strain (NITEBP-771) bacterial cells, bacterial cell culture, or extracts thereof as an oral resident bacteria regulator,
The blending ratio of the Lactobacillus rhamnosus KO3 strain to the entire composition is 0.6 to 2.5% by weight,
An oral composition comprising the oral cavity resident bacteria regulator that selectively acts to suppress the growth of pathogenic bacteria without suppressing the growth of non-pathogenic bacteria in the oral cavity,
The pathogenic bacteria are periodontal pathogenic bacteria Porphyromonas gingivalis and/or Prevotella intermedia,
the non-pathogenic bacterium is a streptococcus of the mitis group selected from Streptococcus mitis and Streptococcus oralis;
It does not contain a non-selective bactericidal agent that has a non-selective bactericidal effect that sterilizes the non-pathogenic bacteria together with the periodontal pathogenic bacteria. An oral composition that selectively acts to inhibit growth .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017128123A JP7445910B2 (en) | 2017-06-29 | 2017-06-29 | Oral compositions, oral care products, and foods containing oral resident bacteria regulators |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017128123A JP7445910B2 (en) | 2017-06-29 | 2017-06-29 | Oral compositions, oral care products, and foods containing oral resident bacteria regulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019011268A JP2019011268A (en) | 2019-01-24 |
| JP7445910B2 true JP7445910B2 (en) | 2024-03-08 |
Family
ID=65227717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017128123A Active JP7445910B2 (en) | 2017-06-29 | 2017-06-29 | Oral compositions, oral care products, and foods containing oral resident bacteria regulators |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7445910B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021172620A (en) * | 2020-04-27 | 2021-11-01 | Ａ Ｌａｖｅｎｄｅｒ．Ｃｏｍ株式会社 | Oral care agent |
| KR102534439B1 (en) * | 2021-04-05 | 2023-05-18 | 주식회사 빅솔 | Composition for inhibiting Biofilm comprising Lactobacillus rhamnosus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011007584A1 (en) | 2009-07-16 | 2011-01-20 | 国立大学法人広島大学 | Prophylactic, ameliorating or therapeutic agent for oral diseases |
-
2017
- 2017-06-29 JP JP2017128123A patent/JP7445910B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011007584A1 (en) | 2009-07-16 | 2011-01-20 | 国立大学法人広島大学 | Prophylactic, ameliorating or therapeutic agent for oral diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019011268A (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1776944B1 (en) | Oral care and food compositions comprising isocamphylcyclohexanol | |
| JP5041135B2 (en) | Oral composition and oral biofilm formation inhibitor | |
| JP5552725B2 (en) | Oral composition and oral biofilm disinfectant | |
| RU2416391C1 (en) | Composition for oral cavity care | |
| KR20200093514A (en) | Oral biofilm formation inhibitor and oral composition | |
| JP3614479B2 (en) | Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them | |
| JP7445910B2 (en) | Oral compositions, oral care products, and foods containing oral resident bacteria regulators | |
| JP7423925B2 (en) | Growth promoter of oral bacteria and composition for oral cavity | |
| JP2007099782A (en) | Antibacterial perfume composition and composition for oral cavity comprising the same | |
| JP2017214296A (en) | Oral composition | |
| JP2017081831A (en) | Antimicrobial agent for oral cavities, and oral composition | |
| WO2019208699A1 (en) | Agent for improving bacterial flora in oral cavity and oral composition | |
| JPH04164021A (en) | Composition for oral cavity | |
| JP6631223B2 (en) | Oral antibacterial agent and oral composition | |
| JPH045222A (en) | Crude drug extract for oral cavity and composition for oral cavity containing the same as active ingredient | |
| WO2021079921A1 (en) | Growth inhibitor for pathogenic bacteria in oral cavity, oral microflora improver, and composition for oral cavity | |
| KR101773227B1 (en) | Dentrifice composition | |
| KR20030009578A (en) | Oral composition for inhibiting the halitosis | |
| JP2017007993A (en) | Oral cavity composition and oral cavity biofilm fungicide | |
| WO2019107168A1 (en) | Dentifrice composition | |
| JP7393823B2 (en) | Oral composition for periodontal disease bacteria | |
| JP6921655B2 (en) | Protease inhibitors, biofilm formation inhibitors, and oral compositions | |
| JP6918529B2 (en) | Oral composition | |
| JP2024030671A (en) | Oral composition | |
| JP2023177682A (en) | Plaque formation inhibitory composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200511 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210309 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210708 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220404 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220405 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220422 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220426 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220603 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230920 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240216 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7445910 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |